LINC01094: A key long non-coding RNA in the regulation of cancer progression and therapeutic targets
Qiang Yi,
Gangfeng Zhu,
Weijian Zhu,
Jiaqi Wang,
Xinting Ouyang,
Kuan Yang,
Yu Fan,
Jinghua Zhong
Affiliations
Qiang Yi
The First Clinical Medical College, Gannan Medical University, Ganzhou, Jiangxi Province, 341000, China
Gangfeng Zhu
The First Clinical Medical College, Gannan Medical University, Ganzhou, Jiangxi Province, 341000, China
Weijian Zhu
The First Clinical Medical College, Gannan Medical University, Ganzhou, Jiangxi Province, 341000, China
Jiaqi Wang
The First Clinical Medical College, Gannan Medical University, Ganzhou, Jiangxi Province, 341000, China
Xinting Ouyang
The First Clinical Medical College, Gannan Medical University, Ganzhou, Jiangxi Province, 341000, China
Kuan Yang
The First Clinical Medical College, Gannan Medical University, Ganzhou, Jiangxi Province, 341000, China
Yu Fan
The First Clinical Medical College, Gannan Medical University, Ganzhou, Jiangxi Province, 341000, China
Jinghua Zhong
Department of Oncology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi Province, 341000, China; Corresponding author. Department of Oncology, The First Affiliated Hospital of Gannan Medical University, 128 Jinling Road, Ganzhou, Jiangxi Province, 341000, China.
LINC01094 is a long non-coding RNA that plays a crucial role in cancer progression by modulating key signaling pathways, such as PI3K/AKT, Wnt/β-catenin and TGF-β Signaling Pathway Feedback Loop. In this review we summarize the recent research on the functional mechanisms of LINC01094 in various cancers, including its impact on tumor growth, metastasis, and resistance to therapy. We also discuss the therapeutic potential of targeting LINC01094 and highlight the current strategies and challenges in this area. Perspectives on future development of LINC01094-based therapies are also provided.
